Posted by Michael Wonder on 24 Jan 2022
Chugai’s Actemra approved for additional indication of SARS-CoV-2 pneumonia in Japan
21 January 2022 - The approval is based on the results of several clinical studies in hospitalised patients with COVID-19.
Chugai Pharmaceutical announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the humanised anti-human IL-6 receptor monoclonal antibody Actemra (tocilizumab) for the additional indication of the treatment of SARS-CoV-2 pneumonia (limited to patients requiring oxygen intervention).
The approval came one month after the application for the additional indication on 13 December 2021.
